

Q1 Total Revenue

**\$90.2M**

FUROSCIX® Q1 Sales

**\$15.5M**

Afrezza® Q1 Sales

**\$15.3M**


UT-Related Revenues

**\$55.8M\***


## Q1 2026 Highlights & Business Updates

- Afrezza Pediatric Indication: PDUFA date May 29, 2026
- FUROSCIX ReadyFlow™ Autoinjector: PDUFA date July 26, 2026
- Completed pilot phase of INHALE-1st pediatric study evaluating Afrezza for newly diagnosed type 1 diabetes
- FDA approved an updated Afrezza label providing starting dose guidance
- Settlement of senior convertible notes
- MNKD-1501 revealed as ralinepag DPI – a collaboration program with United Therapeutics; MNKD received additional \$5M in Q2 for accelerated development
- Nintedanib DPI (MNKD-201) completed enrollment of Cohort 1 in Phase 1b (INFLO-1) study; topline data expected Q3 2026; Anticipate Phase 2 clinical trial (INFLO-2) in IPF to enroll first patient in Q2 2026
- Advancing formulation development of bumetanide DPI (MNKD-701)

## Strategic Evolution



## Catalysts Driving 2026 +



## Well-Positioned for Next Phase of Growth

- 1 Corporate Transformation Underway**  
UT revenue remains a strong foundation; Revenue mix is evolving toward MNKD brands
- 2 FUROSCIX: Expect to Achieve \$110-120M Revenue in 2026**  
Q1 reflects deductible-driven dynamics; FUROSCIX ReadyFlow Autoinjector reflects opportunity to scale revenue trajectory (PDUFA: 7/26/26)
- 3 Afrezza: Pediatric Expansion Unlocks Growth Opportunity**  
Launch-ready for pediatrics (PDUFA: 5/29/26) with targeted sales & marketing investments
- 4 UT Partnership: Durable Base + Expanded Scope**  
Durable Tyvaso DPI economics and potential expansion into IPF; ralinepag DPI adds multi-indication opportunity
- 5 Nintedanib DPI (MNKD-201): Program De-Risking + Global Phase 2 Launch**  
Phase 1b study de-risks program; global Phase 2 trial creates next value driver

NASDAQ  
**MNKD**



To learn more, visit us at:  
[investors.mannkindcorp.com](https://investors.mannkindcorp.com)

MNKD Investor Relations:  
IR@mnkd.com